Vera Therapeutics, Inc. (VERA) Form 10-Q — Aug 10, 2026
Vera Therapeutics reported a Q2 2026 net loss of $109.5 million, or $1.52 per share, up from $76.5 million a year earlier, as G&A expenses surged 139% to $52.4 million to build out sales, marketing and launch infrastructure. Six-month net loss reached $230.5 million with $206.8 million of operating cash used. The filing confirms the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) on July 7, 2026 for IgA nephropathy, based on ORIGIN Phase 3 interim data showing a 46% reduction in proteinuria from baseline and 42% versus placebo.
Key figures
- Total Debt
- 75228000
- Debt Amount
- 75000000
- Total Assets
- 532984000
- Cash Position
- 499.2 million (cash, cash equivalents and marketable securities; cash and equivalents alone were $48.9 million)
- Interest Rate
- 1-Month CME Term SOFR (3.75% floor) + 4.95% per annum; 9.27% nominal at initial funding
- Maturity Date
- June 2030 (extendable to June 2031 upon revenue-based interest-only extension milestone)
- Shares Outstanding
- 72063335
- Atm sales to date
- 0
- Q2 2026 ga expense
- 52410000
- Accumulated deficit
- 991370000
- Q2 2026 rnd expense
- 60080000
- Atm program capacity
- 200000000
- Q2 ga yoy growth pct
- 139
- Loan agreement capacity
- 500000000
- Loan funded outstanding
- 75000000
- Dec 2025 follow on shares
- 7058824
- Unfunded near term tranches
- 125000000
- Dec 2025 follow on net proceeds
- 281300000
- Origin3 proteinuria reduction baseline
- 46%
- Origin3 proteinuria reduction vs placebo
- 42% (p < 0.0001)
Price after filing
Close on the filing date to close N calendar days later (from $32.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.